Novavax, Inc. (NASDAQ:NVAX – Get Free Report) Director James F. Young sold 7,500 shares of the stock in a transaction on Friday, June 21st. The stock was sold at an average price of $14.09, for a total value of $105,675.00. Following the sale, the director now owns 61,760 shares in the company, valued at approximately $870,198.40. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
Novavax Trading Down 6.4 %
Shares of NASDAQ:NVAX opened at $13.11 on Thursday. The company has a 50 day moving average of $11.63 and a 200-day moving average of $7.11. Novavax, Inc. has a one year low of $3.53 and a one year high of $23.86.
Novavax (NASDAQ:NVAX – Get Free Report) last announced its quarterly earnings data on Friday, May 10th. The biopharmaceutical company reported ($1.05) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.04) by ($0.01). The business had revenue of $93.90 million for the quarter, compared to analysts’ expectations of $71.32 million. The business’s revenue was up 15.9% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($3.41) earnings per share. Research analysts forecast that Novavax, Inc. will post 0.49 EPS for the current fiscal year.
Wall Street Analyst Weigh In
View Our Latest Stock Report on NVAX
Institutional Investors Weigh In On Novavax
A number of institutional investors have recently made changes to their positions in the stock. Edgestream Partners L.P. lifted its stake in Novavax by 23.7% in the first quarter. Edgestream Partners L.P. now owns 12,753 shares of the biopharmaceutical company’s stock valued at $61,000 after buying an additional 2,447 shares during the period. Ameritas Investment Partners Inc. raised its position in shares of Novavax by 31.6% in the 1st quarter. Ameritas Investment Partners Inc. now owns 11,298 shares of the biopharmaceutical company’s stock valued at $54,000 after acquiring an additional 2,711 shares during the period. Swedbank AB bought a new position in Novavax during the 1st quarter worth approximately $26,000. Tower Research Capital LLC TRC grew its holdings in Novavax by 102.9% during the fourth quarter. Tower Research Capital LLC TRC now owns 13,944 shares of the biopharmaceutical company’s stock valued at $67,000 after purchasing an additional 7,072 shares during the period. Finally, Price T Rowe Associates Inc. MD increased its stake in Novavax by 17.0% in the first quarter. Price T Rowe Associates Inc. MD now owns 56,065 shares of the biopharmaceutical company’s stock valued at $269,000 after purchasing an additional 8,128 shares in the last quarter. 53.04% of the stock is owned by institutional investors and hedge funds.
About Novavax
Novavax, Inc, a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response.
Recommended Stories
- Five stocks we like better than Novavax
- What is the S&P/TSX Index?
- Stock Impact: McDonald’s Price War with Starbucks, Wendy’s
- Why Special Dividends Can be a Delightful Surprise for Income Investors
- General Mills Q4 Sales Miss Expectations, Triggering Stock Drop
- What is the Dogs of the Dow Strategy? Overview and Examples
- Enovix Stock Rises 35% in Short-Squeeze: This Rally Has Legs
Receive News & Ratings for Novavax Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novavax and related companies with MarketBeat.com's FREE daily email newsletter.